ArticleImmunology1990
Clearance kinetics, tissue localization and fate of IgA-anti-idiotype complexes.
Article in Immunology, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Anti-idiotypic antibody production in hepatitis B vaccine recipients.Journal of gastroenterology · 1994Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To determine the influence of anti-idiotypic antibodies on the complementary idiotype (Id), the clearance kinetics, tissue distribution and fate of idiotype-anti-idiotype complexes were investigated in mice. The complexes were prepared by mixing purified radiolabelled monomeric (mIgA) or polymeric IgA (pIgA) with monoclonal anti-T15 idiotype (B39-38). The 24 hr clearance from circulation of intravenously administered mIgA, mIgA-anti-Id complexes, pIgA and pIgA-anti-Id complexes showed three exponential phases. There was no significant difference in the amount, half-life (t 1/2), or organ distribution of mIgA and mIgA-anti-Id during the first two phases. The mIgA-anti-Id complexes were removed at a faster rate (9.2 +/- 0.5 hr) than the mIgA alone (17.7 +/- 1.3 hr) during the third phase. In contrast, anti-Id affected the clearance of pIgA during the first phase whereby 75% of the administered pIgA-anti-Id complexes, compared with 50% of the pIgA, cleared from the circulation with a t 1/2 of 3 min. This rapid removal from circulation was mediated predominantly by the liver, where 66% of pIgA-anti-Id and 40% of pIgA were detected 10 min after administration of the radiolabelled material. In the second phase, pIgA-anti-Id were removed from circulation at a faster rate (t 1/2 = 28 min) than pIgA (t 1/2 = 43 min). During this phase, 1 hr after administration of radiolabelled material, significantly more pIgA-anti-Id than pIgA were localized in the liver, kidneys, skin and spleen. In contrast, the digestive tract contained more pIgA (22%) than pIgA-anti-Id (11%). Analysis of the mIgA-anti-Id and pIgA-anti-Id by gradient polyacrylamide gel electrophoresis indicated that mIgA-anti-Id were composed of small-sized complexes, while intermediate-sized complexes constituted the majority of the pIgA-anti-Id complexes. These results suggest that the modulatory effect of anti-Id on the complementary IgA idiotype is determined largely by the molecular form of the IgA and the size of the Id-anti-Id complexes.
Indexed as
Identifiers
2335380PMC1385637W2413076959What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.